Literature DB >> 25284101

Rapamycin inhibits oxidative and angiogenic mediators in diabetic retinopathy.

Gökhan Ozdemir1, Metin Kılınç2, Yusuf Ergün3, Elif Sahin2.   

Abstract

OBJECTIVE: To evaluate the role of rapamycin in the prevention of diabetic oxidative stress and the regulation of angiogenic factors.
DESIGN: Experimental animal study.
METHODS: Diabetes was induced in 20 adult male Wistar rats by a single intraperitoneal administration of streptozotocin (60 mg/kg). Rats were randomly assigned into diabetic and rapamycin groups (n = 10). Ten healthy normal adult male rats of same age formed the control group. All groups were followed for 3 months. Rapamycin group received 1 mg/kg rapamycin via orogastric gavage during the last 4 weeks. At the end of 12 weeks, rats were sacrificed and biochemical oxidative stress markers (malondialdehyde and nitrotyrosine), together with vascular endothelial growth factor, hypoxia-inducible factor-1α, and pigment epithelium-derived factor, were measured in the retina. Blood biochemical analyses were also done.
RESULTS: In the diabetic group, retinal malondialdehyde and nitrotyrosine levels were increased in comparison with control and rapamycin groups (p < 0.05). Rapamycin suppressed oxidative stress and showed a beneficial effect. It also decreased all angiomodulator cytokines compared with the diabetic group (p < 0.05). Correspondingly, rapamycin also decreased plasma malondialdehyde levels compared with the diabetic group (p = 0.037).
CONCLUSIONS: Rapamycin may have a protective role against diabetes-induced oxidative retinal injury and may decrease angiomodulator cytokines.
Copyright © 2014 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25284101     DOI: 10.1016/j.jcjo.2014.07.003

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  9 in total

Review 1.  Association between endoplasmic reticulum stress and risk factors of diabetic retinopathy.

Authors:  De-Qian Kong; Li Li; Yue Liu; Guang-Ying Zheng
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

2.  Rapamycin inhibits Erk1/2-mediated neuronal apoptosis caused by cadmium.

Authors:  Chong Xu; Hai Zhang; Chunxiao Liu; Yu Zhu; Xiaoxue Wang; Wei Gao; Shile Huang; Long Chen
Journal:  Oncotarget       Date:  2015-08-28

3.  Survival or death: a dual role for autophagy in stress-induced pericyte loss in diabetic retinopathy.

Authors:  Dongxu Fu; Jeremy Y Yu; Shihe Yang; Mingyuan Wu; Samar M Hammad; Anna R Connell; Mei Du; Junping Chen; Timothy J Lyons
Journal:  Diabetologia       Date:  2016-07-30       Impact factor: 10.122

4.  Different contributions of autophagy to retinal ganglion cell death in the diabetic and glaucomatous retinas.

Authors:  Hae-Young Lopilly Park; Jie Hyun Kim; Chan Kee Park
Journal:  Sci Rep       Date:  2018-09-06       Impact factor: 4.379

5.  Carbamazepine Alleviates Retinal and Optic Nerve Neural Degeneration in Diabetic Mice via Nerve Growth Factor-Induced PI3K/Akt/mTOR Activation.

Authors:  Nehal M Elsherbiny; Yousra Abdel-Mottaleb; Amany Y Elkazaz; Hoda Atef; Rehab M Lashine; Amal M Youssef; Wessam Ezzat; Sabah H El-Ghaiesh; Rabie E Elshaer; Mohamed El-Shafey; Sawsan A Zaitone
Journal:  Front Neurosci       Date:  2019-11-01       Impact factor: 4.677

Review 6.  The Evolving Treatment of Diabetic Retinopathy.

Authors:  Sam E Mansour; David J Browning; Keye Wong; Harry W Flynn; Abdhish R Bhavsar
Journal:  Clin Ophthalmol       Date:  2020-03-04

7.  Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin.

Authors:  Teruyo Kida; Hidehiro Oku; Sho Osuka; Taeko Horie; Tsunehiko Ikeda
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

Review 8.  mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular Neurodegenerative Diseases.

Authors:  Yipin Wang; Nicholas Siu Kay Fung; Wai-Ching Lam; Amy Cheuk Yin Lo
Journal:  Antioxidants (Basel)       Date:  2022-06-29

Review 9.  Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy.

Authors:  Mark T Bolinger; David A Antonetti
Journal:  Int J Mol Sci       Date:  2016-09-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.